Treatment of Staphylococcus aureus endocarditis using moxifloxacin.
The conventional treatment of staphylococcal endocarditis requires in-patient administration, is inconvenient, and is potentially toxic. Increasing experience with well-absorbed, well-tolerated and highly active agents such as the new quinolones has prompted interest in their use as therapeutic alternatives for the treatment of such infections. We describe a case of staphylococcal endocarditis which failed to respond to conventional therapy, but where the addition of moxifloxacin, an 8-methoxyquinolone, was curative.
Berrington
A W
AW
Department of Medical Microbiology, Freeman Hospital, Newcastle upon Tyne, UK. andrew@corstopitum.freeserve.co.uk
Koerner
R J
RJ
Perry
J D
JD
Bain
H H
HH
Gould
F K
FK
D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001372:Aza Compounds; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D000077266:Moxifloxacin; D011804:Quinolines; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000302:isolation & purification*
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin